Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute
treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally
advanced NPC. Three hundreds and twenty patients will be recruited into this study.
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Collaborators:
Fujian Province Tumor Hospital The First Affiliated Hospital of Xiamen University